ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO697

A Single Center Validation Study of a Korean Version of the SARC-F for Patients on Peritoneal Dialysis

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis


  • Seo, Joonhyuk, Yeungnam University Medical Center, Daegu, Korea (the Republic of)
  • Kang, Seok hui, Yeungnam University Medical Center, Daegu, Korea (the Republic of)
  • Cho, Kyu-hyang, Yeungnam University Medical Center, Daegu, Korea (the Republic of)
  • Park, Jong-Won, Yeungnam University Medical Center, Daegu, Korea (the Republic of)
  • Do, Jun-Young, Yeungnam University Medical Center, Daegu, Korea (the Republic of)

The SARC-F is a simple screening tool for sarcopenia, consisting of 5 questions covering strength, assistance in walking, rising from a chair, climbing stairs, and falls. Given most of those on peritoneal dialysis (PD) have low muscle mass and poor physical function, it is worth examing an usefulness of SARC-F for them. This study aimed to validate the Korean version of SARC-F for patients on PD.


The Korean version of SARC-F, which was introduced from a previous study validating it in community-dwelling older adults, was tested in regular visiting 127 outpatients on PD (men 52.8%, women 47.2%). Validity was analyzed by standard criteria based on the Foundation for the National Institutes of Health, Asian and European Working Group. The subjects were divided into two groups according to SARC-F score (<4 and ≥4) and its correlation with multiple factors including age, KT/V, residual renal function, skeletal muscle mass, handgrip strength, etc. was inspected by sex.


The prevalence of sarcopenia in men and women according to SARC-F was 14.9% and 31.6%, respectively. For men, SARC-F showed low sensitivity and low positive predictive value (PPV) [33.3%-66.7%, 10.0%-20.0%, respectively], but high specificity and high negative predictive value (NPV) [85.9%-87.5%, 94.7%-98.2%, respectively]. Similary, for women, SARC-F showed low sensitivity, low PPV and high NPV [50.0%-80.0%, 5.3%-21.1%, 97.6%, respectively], although specificity was relatively lower than men [69.0%-72.7%]. The SARC-F<4 group had less muscle mass and poorer hand grip strength.


As the specificity and NPV of Korean version of SARC-F were high, it is useful, particularly for men on PD, to rule out sarcopenia in a simple way. Regarding the lower specificity for women, it is suggestive that applying a different cut-off value according to sex is necessary. The sensitivity was too low to screen the sarcopenic patient on PD, and hence, further attention for screening sarcopenia would be required.